西班牙专利ES2700448A2 Sigma ligands for use in the treatment of diabetes and metabolic syndrome

专利PDF首页>>西班牙专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
The invention relates to compounds of general formula (I) having pharmacological activity towards the sigma receptor, for use in the treatment of diabetes.
公开号:ES2700448A2
申请号:ES201890077
申请日:2017-06-05
公开日:2019-02-15
发明作者:Manuel Merlos-Roca；Maria-Isabel Martin-Fontelles；Carlos-Ramón Plata-Salaman
申请人:Esteve Pharmaceuticals SA；
IPC主号:

专利说明:

[0001]
[0002] USE OF SIGMA RECEIVER LIGANDS IN DIABETES AND METABOLIC SYNDROME
[0003]
[0004] FIELD OF THE INVENTION
[0005] The present invention relates to the use of ligands of the sigma receptor and more particularly to some pyrazole derivatives and to the use of pharmaceutical compositions comprising them for the treatment of diabetes.
[0006]
[0007] BACKGROUND OF THE INVENTION
[0008] Diabetes is a metabolic disorder caused by the interaction of genetic, environmental, immunological, as well as lifestyle factors. In 2004, according to the World Health Organization (WHO), more than 150 million people worldwide suffer from diabetes. Its incidence is increasing rapidly and it is estimated that by the year 2025 this number will double. According to the American Diabetes Association (ADA; http://www.diabetes.org/home.jsp) four main categories of diabetes have been identified, including:
[0009] Diabetes mellitus type 1: The body can not produce insulin.
[0010]
[0011] Type 2 diabetes mellitus: It arises as a result of insulin resistance, combined with a relative deficiency of insulin.
[0012]
[0013] Gestational diabetes: It happens during pregnancy.
[0014]
[0015] Glucose intolerance (ie, prediabetes): When blood glucose levels are higher than normal but not high enough for a diagnosis of type 2 diabetes.
[0016]
[0017] In the pathological course of diabetes, additional complications can often arise, such as peripheral vascular disease, diabetic neuropathy, diabetic foot problems, diabetic retinopathy and nephropathy.
[0018]
[0019] One of the most common complications of diabetes is peripheral neuropathy. Globally, it affects approximately 20-30 million people and with the increase in obesity rates and the prevalence of type 2 diabetes, it could double by the year 2025 (Said, 2007).
[0020] In the development of diabetes, a series of pathogenic processes are involved, ranging from the autoimmune destruction of p cells of the pancreas to failures that cause resistance to the action of insulin. The basis of the abnormalities in the metabolism of carbohydrates, lipids and proteins in diabetes is the deficient action of this hormone in the target tissues. Insulin secretion deficiency and defect in insulin action often coexist in the same patient; therefore, it is not possible to determine what is the main cause of hyperglycemia (American Diabetes Association, 2013).
[0021]
[0022] Hyperglycemia induces macrovascular disorders (myocardial infarction, stroke and peripheral vascular disease) and microvascular dysfunction causes damage to specific cell groups, such as vascular endothelial cells in the retina, mesangial in renal glomeruli, neuronal axons and Schwann cells in Peripheral nerves, causing retinopathy, nephropathy and neuropathy respectively (Méndez et al., 2014). In addition, autonomic neuropathy, which involves the nervous system both sympathetic and parasympathetic, causes gastrointestinal symptoms and urogenital, cardiovascular and sexual dysfunction (American Diabetes Association, 2013).
[0023]
[0024] In its initial phase, type 2 diabetes is asymptomatic and can be diagnosed after a long time. In this period, the disease could be demonstrated by measuring the fasting glucose tests or by making a tolerance to it, because the hyperglycemia develops gradually. In these early stages, although the typical symptoms of the disease are not shown, macro and microvascular complications may develop (American Diabetes Association, 2013).
[0025]
[0026] Type 2 diabetes is usually associated with the metabolic syndrome (MS); which comprises abdominal obesity, hyperglycemia, hypertriglyceridemia or reduction of HDL cholesterol bound thereto. Although its specific etiology is unknown, there are probably many different causes; Most of these patients are obese or have a higher percentage of fat in the abdominal region, which causes insulin resistance. Risk factors include age, obesity and physical inactivity; It is also more common in women with a history of gestational diabetes and in people with hypertension or dyslipidemia (Federation, 2014, Roberts et al., 2013).
[0027]
[0028] The treatment of the metabolic syndrome is of great importance in medicine. Metabolic syndrome is a widespread disease, particularly in the United States and Europe. Based on data from census surveys for the years 1988 to 1994 and 2000, the American Center for Disease Control and Prevention estimates that 47 million people in the United States suffer from metabolic syndrome. Currently there is a worldwide need for the treatment of this syndrome since it has been identified that it increases the risk of cardiovascular mortality.
[0029]
[0030] Accordingly, it is an object of the present invention to provide medicaments that are suitable for the treatment of the metabolic syndrome and more particularly to the metabolic syndrome associated with diabetes, preferably to type 2 diabetes. Another aspect of the present invention is to provide suitable medicaments. for the treatment of diabetes, and more particularly of type 2 diabetes. Another aspect of the present invention is to provide appropriate medicaments for controlling glycemia associated with diabetes by reducing glucose levels. Another aspect of the present invention is to provide appropriate drugs in adjuvant therapy of diabetes. Another aspect of the present invention is to provide medicaments suitable for the treatment of hyperglycemia.
[0031]
[0032] The sigma receptor (a) is a receptor for the endoplasmic reticulum and the cell surface expressed in the central nervous system (CNS) among other tissues. From studies of the biology and function of sigma receptors, evidence has been presented that sigma receptor ligands may be useful in the treatment of psychoses and motor disorders, such as dystonia and tardive dyskinesia, and motor disorders. associated with Huntington's chorea or Tourette's syndrome; and in Parkinson's disease (Walker, JM et al., Pharmacological Reviews, 1990, 42, 355). It has been reported that the known ligand of sigma rimcazole receptor shows clinical effects in the treatment of psychosis (Hanner, M. et al., Proc. Natl. Acad. Sci., 1996, 93: 8072-8077; Snyder, SH, Largent , BL J. Neuropsychiatry 1989, 1, 7). The sigma binding sites have preferential affinity for the dextrorotatory isomers of certain opioid benzomorphanes, such as (+) SKF 10047, (+) cyclazocine and (+) pentazocine, and also by some narcoleptics such as haloperidol.
[0033]
[0034] The sigma receptor has at least two subtypes, which can be differentiated by stereoselective isomers of these pharmacoactive drugs. SKF 10047 has nanomolar affinity for the sigma 1 (a-1) site and has micromolar affinity for the sigma site (a-2). Haloperidol has similar affinities for both subtypes. The endogenous sigma ligands are not known, although it has been suggested that progesterone is one of them. Possible pharmacological effects mediated by the sigma site include modulation of glutamate receptor function, neurotransmitter response, neuroprotection and cognition (Quirion, R. et al. Trends Pharmacol. Sci., 1992, 13: 85-86). The existence of sigma receptors in the CNS, the immune system and the endocrine system has suggested the likelihood that they can serve as a link between the three systems.
[0035]
[0036] The presence of sigma-1 receptor (a1R) in the rat pancreas has been described by the use of the a1R radiotracer, 18F-FTC-146 (James et al., 2014).
[0037] Although it is known that some ligands of the nonselective sigma receptor promote the release of insulin from isolated rat islets (Chan and Morgan, 1998), the pathophysiological relevance of a1R in pancreatic function or in glycemic control has not yet been determined. .
[0038]
[0039] A family of pyrazole derivatives that are particularly selective inhibitors of the sigma-1 receptor have been discovered.
[0040] This family has a pyrazole group which is characterized by the substitution at position 3 by an alkoxy group directly attached to nitrogen. These compounds were described in WO 2006/021462.
[0041]
[0042] SUMMARY OF THE INVENTION
[0043] It has been surprisingly discovered that the ligands of the sigma receptor of the invention are effective for the treatment of diabetes.
[0044] It has been surprisingly discovered that the ligands of the sigma receptor of the invention are effective for the treatment of diabetes, in particular to control the associated glycaemia by reducing blood glucose levels.
[0045] It has also been surprisingly discovered that the ligands of the sigma receptor of the invention can be used as adjuvant therapy in the treatment of diabetes.
[0046] It was also surprisingly discovered that the ligands of the sigma receptor of the invention are effective in treating the metabolic syndrome and more particularly the metabolic syndrome associated with diabetes.
[0047] It has surprisingly been found that the ligands of sigma receptors of the invention are effective in the treatment of hyperglycemia.
[0048] In accordance with the present invention, the term "diabetes" preferably refers to type 2 diabetes.
[0049]
[0050] Therefore, in one aspect, the invention relates to a compound that binds to the sigma receptor for use in the treatment of diabetes.
[0051] In another preferred aspect, the invention relates to a compound that binds to the sigma receptor according to the general formula (I) for use in the treatment of diabetes:
[0052]
[0053]
[0054]
[0055] where
[0056] Ri is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, unsubstituted or substituted non-aromatic heterocyclyl, heterocyclyl substituted or unsubstituted aromatic, substituted or unsubstituted heterocyclylalkyl, -COR8, -C (O) OR8,
[0057] -C (O) NR8R9, -CH = NR8, -CN, -OR8, -OC (O) R8, -S (O) tR8, -NR8R9, -NR8C (O) R9, -NO2, -N = CR8R9 and halogen;
[0058]
[0059] R2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aromatic or non-aromatic heterocyclyl , substituted or unsubstituted heterocyclylalkyl, - COR8, -C (O) OR8, -C (O) NR8R9, -CH = NR8, -CN, -OR8, -OC (O) R8, -S (O) t-R8 , -NR8R9, -NR8C (O) R9, -NO2, -N = CR8R9 and halogen;
[0060]
[0061] R3 and R4 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, aromatic or substituted non-aromatic heterocyclyl or unsubstituted, substituted or unsubstituted heterocyclylalkyl, -COR8, -C (O) OR8, -C (O) NR8R9, -CH = NR8, -CN, -OR8, -OC (O) R8, -S (O) t-R8, -NR8R9, -NR8C (O) R9, -NO2, -N = CR8R9 and halogen or together form an optional fused ring system replaced;
[0062]
[0063] R5 and R6 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, aromatic or substituted non-aromatic heterocyclyl or unsubstituted, substituted or unsubstituted heterocyclylalkyl, -COR8, -C (O) OR8, -C (O) NR8R9, -CH = NR8, -CN, -OR8, -OC (O) R8, -S (O) t-R8, -NR8R9, -NR8C (O) R9, -NO2, -N = CR8R9 and halogen or together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted aromatic or non-aromatic heterocyclyl group;
[0064]
[0065] n is selected from 1,2, 3, 4, 5, 6, 7 or 8;
[0066]
[0067] t is 1, 2 or 3;
[0068]
[0069] R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy , substituted or unsubstituted aryloxy and halogen;
[0070]
[0071] or one of its pharmaceutically acceptable salts, isomers, prodrugs or solvates.
[0072]
[0073] In another aspect, the invention relates to a compound that binds to the sigma receptor, in particular those of general formula (I) for use in the control of glycemia associated with diabetes by reducing blood glucose levels.
[0074]
[0075] In another aspect, the invention relates to a compound that binds to the sigma receptor, in particular those of general formula (I) for use in the treatment of the metabolic syndrome, preferably the metabolic syndrome associated with diabetes.
[0076]
[0077] In another aspect, the invention relates to a compound that binds to the sigma receptor, in particular those of general formula (I) for use as adjuvant therapy in the treatment of diabetes.
[0078] In another aspect, the invention relates to a compound that binds to the sigma receptor, in particular those with general formula (I), for use in the treatment of hyperglycemia.
[0079]
[0080] In another aspect, the invention relates to the use in the treatment of diabetes of a pharmaceutical composition comprising at least one compound as defined above, wherein the composition further comprises at least one pharmaceutically carrier, adjuvant and / or carrier. acceptable.
[0081]
[0082] In another aspect, the invention relates to the use in the control of glycemia associated with diabetes by reducing the blood glucose levels of a pharmaceutical composition comprising at least one compound as defined above, wherein the composition further comprises at least one carrier, adjuvant and / or pharmaceutically acceptable carrier.
[0083]
[0084] In another aspect, the invention relates to the use for treating the metabolic syndrome, in particular, the metabolic syndrome associated with diabetes of a pharmaceutical composition comprising at least one compound as defined above, wherein the composition further comprises less a pharmaceutically acceptable carrier, adjuvant and / or carrier.
[0085]
[0086] In another aspect, the invention relates to the use as adjuvant therapy in the treatment of diabetes of a pharmaceutical composition comprising at least one compound as defined above, wherein the composition further comprises at least one carrier, adjuvant and / or pharmaceutically acceptable vehicle.
[0087]
[0088] In another aspect, the invention relates to the use in the treatment of hyperglycemia of a pharmaceutical composition comprising at least one component as defined above, wherein the composition further comprises at least one carrier, adjuvant and / or carrier. pharmaceutically acceptable.
[0089]
[0090] In a preferred embodiment of the use as defined above, the compound is selected from a sigma receptor antagonist, a neutral antagonist, a reverse antagonist or a partial antagonist.
[0091]
[0092] In a preferred embodiment of the use as defined above, the compound is selected from selective ligands of the neutral sigma antagonist receptor.
[0093] In a preferred embodiment of the use as defined above, the compound binds selectively to the sigma-1 receptor subtype.
[0094] Another aspect of the invention is a method of treating a patient suffering from diabetes, comprising administering to the patient in need of such treatment a therapeutically effective amount of a sigma ligand, preferably a sigma ligand of formula (I) as defined above. .
[0095]
[0096] Another aspect of the invention is a method of treating a patient suffering from diabetes by controlling glycemia associated with diabetes by reducing blood glucose levels, which comprises administering to the patient in need of said treatment a therapeutically effective amount of a ligand. of sigma, preferably a sigma ligand of formula (I) as defined above.
[0097]
[0098] Another aspect of the invention is a method of treating a patient suffering from diabetes, comprising administering to the patient in need of such treatment a therapeutically effective amount of a sigma ligand, preferably a sigma ligand of formula (I) as defined previously as adjuvant therapy.
[0099]
[0100] Another aspect of the invention is a method of treating a patient suffering from the metabolic syndrome, in particular, metabolic syndrome associated with diabetes, which comprises administering to the patient in need of such treatment a therapeutically effective amount of a sigma ligand, preferably a ligand. sigma of formula (I) as defined above.
[0101]
[0102] Another aspect of the invention is a method of treating a patient suffering from hyperglycemia, comprising administering to the patient in need of such treatment a therapeutically effective amount of a sigma ligand, preferably a sigma ligand of formula (I) as defined above. .
[0103] The preferences and embodiments mentioned above can be combined to obtain other preferred compounds or uses.
[0104]
[0105] These aspects and preferred embodiments thereof are further defined below in the detailed description and claims.
[0106] BRIEF DESCRIPTION OF THE FIGURES
[0107]
[0108] Figure 1: Evolution of glycemia and body weight gain in ZDF treated with saline or with Example 1 and LEAN rats. The lines represent the mean ± DTM of glucose levels at weeks 7, 10, 13, 14 and 15.
[0109]
[0110] DETAILED DESCRIPTION OF THE INVENTION
[0111] In one aspect, the invention relates to a compound that binds to the sigma receptor, for use in the treatment of diabetes and more specifically to type 2 diabetes. Another aspect of the present invention relates to a compound that it binds to the sigma receptor for use in the treatment of the metabolic syndrome, and more specifically to the metabolic syndrome associated with diabetes, preferably to type 2 diabetes. Another aspect of the present invention relates to a compound that binds to the metabolic syndrome. sigma receptor for use in the control of glycemia associated with diabetes by lowering blood glucose levels. Another aspect of the present invention relates to a compound that binds to the sigma receptor for use in adjuvant therapy of diabetes. Another aspect of the present invention relates to a compound that binds to the sigma receptor for use in the treatment of hyperglycemia.
[0112]
[0113] The term "compound that binds to the sigma receptor" refers to any compound that binds with a high affinity to the sigma receptor, preferably to the sigma-1 receptor subtype.
[0114]
[0115] The term "high affinity binding to the sigma receptor" refers to compounds of the invention that can replace a ligand in competitive binding assays, preferably in competitive radioligand binding assays such as those described in WO2006 / 021462, for example, in a1 receptor binding assays performed as described (DeHaven-Hudkins et al., Eur J Pharmacol, 1992, 227, 371) or a2 receptor binding assays such as those described (Radesca et al. ., J Med Chem, 1991, 34, 3058). Preferably, the binding of the compounds of the invention, with respect to binding to the sigma-1 receptor subtype, is measured by competition with the binding of 3 [H] - (+) - pentazocine, for example, in radioligand assays such as described in the art (for example, in DeHaven-Hudkins et al., 1992). Preferably, the compounds of the invention when evaluated at a concentration of 10-7 M provided at least 25%, more preferably at least 45%, even more preferably at least 65%, even more preferably at least 75%. %, even more preferably at least 85% of binding to the sigma-1 receptor in radioligand 3 [H] - (+) - pentazocine assays as defined above.
[0116]
[0117] The term "that selectively binds to the sigma receptor" refers to compounds of the invention that exhibit nanomolar affinity for their target, while showing well a percentage inhibition of less than 50% when assayed at 1 micromolar in a panel of other non-specific targets or when there is a hundred times less affinity or functional activity for those non-specific targets.
[0118]
[0119] Thus, in one aspect the compound that binds to the sigma receptor, preferably the sigma 1 receptor subtype, is used in the treatment of diabetes, and more particularly type 2 diabetes. In another aspect, the compound that binds to the receptor sigma, preferably the subtype of sigma receptor 1, is used in the treatment of the metabolic syndrome, and more particularly the metabolic syndrome associated with diabetes, preferably type 2 diabetes. In another aspect the compound that binds to the sigma receptor, preferably at subtype of sigma 1 receptor, is used to control glycemia associated with diabetes by lowering glucose levels. In another aspect, the compound that binds to the sigma receptor, preferably to the sigma 1 receptor subtype, is used as adjuvant therapy for diabetes. In another aspect the compound that binds to the sigma receptor, preferably to the sigma 1 receptor subtype, is used in the treatment of hyperglycemia.
[0120]
[0121] In a preferred embodiment of the use as defined above, the compound is a compound according to formula I:
[0122]
[0123]
[0124]
[0125]
[0126] where
[0127] Ri is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, unsubstituted or substituted non-aromatic heterocyclyl, heterocyclyl substituted or unsubstituted aromatic, substituted or unsubstituted heterocyclylalkyl, -COR8, -C (O) OR8,
[0128] -C (O) NR8R9, -CH = NR8, -CN, -OR8, -OC (O) R8, -S (O) tR8, -NR8R9, -NR8C (O) R9, -NO2, -N = CR8R9 and halogen;
[0129]
[0130] R2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aromatic or non-aromatic heterocyclyl , substituted or unsubstituted heterocyclylalkyl, - COR8, -C (O) OR8, -C (O) NR8R9, -CH = NR8, -CN, -OR8, -OC (O) R8, -S (O) t-R8 , -NR8R9, -NR8C (O) R9, -NO2, -N = CR8R9 and halogen;
[0131]
[0132] R3 and R4 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, aromatic or substituted non-aromatic heterocyclyl or unsubstituted, substituted or unsubstituted heterocyclylalkyl, -COR8, -C (O) OR8, -C (O) NR8R9, -CH = NR8, -CN, -OR8, -OC (O) R8, -S (O) t-R8, -NR8R9, -NR8C (O) R9, -NO2, -N = CR8R9 and halogen or together form an optionally substituted fused ring system;
[0133]
[0134] R5 and R6 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, aromatic or substituted non-aromatic heterocyclyl or unsubstituted, substituted or unsubstituted heterocyclylalkyl, -COR8, -C (O) OR8, -C (O) NR8R9, -CH = NR8, -CN, -OR8, -OC (O) R8, -S (O) t-R8, -NR8R9, -NR8C (O) R9, -NO2, -N = CR8R9 and halogen or together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted aromatic or non-aromatic heterocyclyl group;
[0135]
[0136] n is selected from 1,2, 3, 4, 5, 6, 7 or 8;
[0137] t is 1, 2 or 3;
[0138] R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy , substituted or unsubstituted aryloxy and halogen;
[0139]
[0140] or one of its pharmaceutically acceptable salts, isomers, prodrugs or solvates.
[0141]
[0142] In a preferred embodiment of the use as defined above, the compound is characterized in that R1 is selected from H, -COR8 or substituted or unsubstituted alkyl, preferably selected from H, methyl or acetyl.
[0143]
[0144] In a preferred embodiment of the use as defined above, the compound is characterized in that R1 is hydrogen.
[0145]
[0146] In a preferred embodiment of the use as defined above, the compound is characterized in that R2 is H or alkyl, preferably methyl or H.
[0147]
[0148] In a preferred embodiment of the use as defined above, the compound is characterized in that R3 and R4 are located in the meta and para positions of the phenyl group.
[0149]
[0150] In a preferred embodiment of the use as defined above, the compound is characterized in that R3 and R4 are independently selected from halogen or substituted or unsubstituted alkyl, more preferably, they are selected from halogen or haloalkyl.
[0151]
[0152] In an especially preferred embodiment of the use as defined above the compound is characterized in that both R3 and R4 together with the phenyl group form an optionally substituted fused ring system. More preferably, said fused ring system is selected from a substituted or unsubstituted fused aryl group and an aromatic or partially aromatic, substituted or unsubstituted fused heterocyclyl group. Said fused ring system preferably contains two rings and / or from 9 to about 18 ring atoms, more preferably 9 or 10 ring atoms. Even more preferably, the fused ring system is naphthyl, especially a 2-naphthyl ring system, substituted or unsubstituted.
[0153] In a preferred embodiment of the use as defined above, the compound is characterized in that n is selected from 2, 3 and 4, more preferably n is 2.
[0154]
[0155] In a preferred embodiment of the use as defined above, the compound is characterized in that R5 and R6, together, form a morpholin-4-yl group.
[0156]
[0157] In a preferred variant of the invention, the sigma ligand of general formula (I) is selected from:
[0158] [1] 4- {2- (1- (3,4-Dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy) ethyl} morpholine,
[0159] [2] 2- [1- (3,4-Dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy] -N, N-diethylethanamine hydrochloride, [3] 1- (3,4-dichlorophenyl) hydrochloride ) -5-methyl-3- [2- (pyrrolidin-1-yl) ethoxy] -1H-pyrazole,
[0160] [4] 1- (3,4-Dichlorophenyl) -5-methyl-3- [3- (pyrrolidin-1-yl) propoxy] -1H-pyrazole hydrochloride,
[0161] [5] 1- {2- [1- (3,4-Dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy] ethyl} piperidine,
[0162] [6] 1- {2- [1- (3,4-Dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy] ethyl} -1H-imidazole,
[0163] [7] 3- {1- [2- (1- (3,4-Dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy) ethyl] piperidin-4-yl} -3H-imidazo [4.5 -b] pyridine,
[0164] [8] 1- {2- [1- (3,4-Dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy] ethyl} -4-methylpiperazine,
[0165] [9] ethyl 4- {2- [1- (3,4-dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy] ethyl} piperazine carboxylate, [10] 1- (4- (2- ( 1- (3,4-dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy) ethyl) piperazin-1-yl) ethanone, [11] 4- {2- [1- (4-methoxyphenyl) hydrochloride) -5-methyl-1H-pyrazol-3-yloxy] ethyl} morpholine,
[0166] [12] 1- (4-methoxyphenyl) -5-methyl-3- [2- (pyrrolidin-1-yl) ethoxy] -1H-pyrazole,
[0167] [13] 1- (4-methoxyphenyl) -5-methyl-3- [3- (pyrrolidin-1-yl) propoxy] -1H-pyrazole,
[0168] [14] 1- [2- (1- (4-methoxyphenyl) -5-methyl-1H-pyrazol-3-yloxy) ethyl] piperidine,
[0169] [15] 1- {2- [1- (4-methoxyphenyl) -5-methyl-1H-pyrazol-3-yloxy] ethyl} -1H-imidazole,
[0170] [16] 4- {2- [1- (3,4-Dichlorophenyl) -5-phenyl-1H-pyrazol-3-yloxy] ethyl} morpholine hydrochloride,
[0171] [17] 1- (3,4-dichlorophenyl) -5-phenyl-3- [2- (pyrrolidin-1-yl) ethoxy] -1H-pyrazole hydrochloride,
[0172] [18] 1- (3,4-dichlorophenyl) -5-phenyl-3- [3- (pyrrolidin-1-yl) propoxy] -1H-pyrazole,
[0173] [19] 1- {2- [1- (3,4-Dichlorophenyl) -5-phenyl-1H-pyrazol-3-yloxy] ethyl} piperidine,
[0174] [20] 1- {2- [1- (3,4-Dichlorophenyl) -5-phenyl-1H-pyrazol-3-yloxy] ethyl} -1H-imidazole hydrochloride, [21] 2- {2- hydrochloride] [1- (3,4-dichlorophenyl) -5-phenyl-1H-pyrazol-3-yloxy] ethyl} -1,2,3,4-tetrahydroisoquinoline,
[0175] [22] 4- {4- [1- (3,4-Dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy] butyl} morpholine hydrochloride, [23] 1- (3,4-dichlorophenyl) - 5-methyl-3- [4- (pyrrolidin-1-yl) butoxy] -1H-pyrazole,
[0176] [24] 1- {4- [1- (3,4-Dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy] butyl} piperidine hydrochloride, [25] 1- [4- [1- (3,4-dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy] butyl} -4-methylpiperazine,
[0177] [26] 1- {4- [1- (3,4-Didorophenyl) -5-methyl-1H-pyrazol-3-yloxy] butyl} -1H-imidazole,
[0178] [27] 4- [1- (3,4-Didorophenyl) -5-methyl-1H-pyrazol-3-yloxy] -N, N-diethylbutan-1-amine,
[0179] [28] 1- {4- [1- (3,4-Didorophenyl) -5-methyl-1H-pyrazol-3-yloxy] butyl} -4-phenylpiperidine hydrochloride,
[0180] [29] 1- {4- [1- (3,4-Didorophenyl) -5-methyl-1H-pyrazol-3-yloxy] butyl} -6,7-dihydro-1H-indole-4 (5H) -one ,
[0181] [30] 2- {4- [1- (3,4-dichlorophenyl) -5-methyMH-pyrazol-3-yloxy] butyl} -1,2,3,4-tetrahydroisoquinoline,
[0182] [31] 4- {2- [1- (3,4-Dichlorophenyl) -5-isopropyl-1H-pyrazol-3-yloxy] ethyl} morpholine hydrochloride, [32] 2- [1- (3,4- dichlorophenyl) -5-isopropyl-1H-pyrazol-3-yloxy] -N, N-diethylethanamine,
[0183] [33] 1- (3,4-Dichlorophenyl) -5-isopropyl-3- [2- (pyrrolidin-1-yl) ethoxy] -1H-pyrazole hydrochloride, [34] 1- (3,4-) hydrochloride dichlorophenyl) -5-isopropyl-3- [3- (pyrrolidin-1-yl) propoxy] -1H-pyrazole, [35] 1- {2- [1- (3,4-dichlorophenyl) -5-isopropyl-1H -pyrazol-3-yloxy] ethyl} piperidine,
[0184] [36] 2- {2- [1- (3,4-Dichlorophenyl) -5-isopropy-M-pyrazol-3-yloxy] ethyl} -1,2,3,4-tetrahydroisoquinoline hydrochloride,
[0185] [37] 4- {2- [1- (3,4-Dichlorophenyl) -1H-pyrazol-3-yloxy] ethyl} morpholine,
[0186] [38] 2- [1- (3,4-dichlorophenyl) -1H-pyrazol-3-yloxy] N, N-diethylethanamine,
[0187] [39] 1- (3,4-dichlorophenyl) -3- [2- (pyrrolidin-1-yl) ethoxy] -1H-pyrazole,
[0188] [40] 1- {2- [1- (3,4-dichlorophenyl) -1H-pyrazol-3-yloxy] ethyl} piperidine,
[0189] [41] 1- (3,4-dichlorophenyl) -3- [3- (pyrrolidin-1-yl) propoxy] -1H-pyrazole,
[0190] [42] 1- {2- [1- (3,4-Dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy] ethyl} piperazine dihydrochloride, [43] 1- {2- [1- (3 , 4-dichlorophenyl) -5-methyl-1H-pyrazol-3-yloxy] ethyl} pyrrolidin-3-amine,
[0191] [44] 4- {2- [1- (3,4-Dichlorophenyl) -4,5-dimethyl-1H-pyrazol-3-yloxy] ethyl} morpholine,
[0192] [45] 2- [1- (3,4-Dichlorophenyl) -4,5-dimethyl-1H-pyrazol-3-yloxy] -N, N-diethylethanamine hydrochloride,
[0193] [46] 1- (3,4-Dichlorophenyl) -4,5-dimethyl-3- [2- (pyrrolidin-1-yl) ethoxy] -1H-pyrazole hydrochloride, [47] hydrochloride of 1- (3, 4-Dichlorophenyl) -4,5-dimethyl-3- [3- (pyrrolidin-1-yl) propoxy] -1H-pyrazole, [48] 1- {2- [1- (3,4-dichlorophenyl) -4 , 5-dimethyl-1H-pyrazol-3-yloxy] ethyl} piperidine,
[0194] [49] 4- {4- [1- (3,4-Dichlorophenyl) -1H-pyrazol-3-yloxy] butyl} morpholine hydrochloride,
[0195] [50] (2S, 6R) -4- {4- [1- (3,4-dichlorophenyl) -1H-pyrazol-3-yloxy] butyl} -2,6-dimethylmorpholine hydrochloride,
[0196] [51] 1- {4- [1- (3,4-Dichlorophenyl) -1H-pyrazol-3-yloxy] butyl} piperidine hydrochloride,
[0197] [52] 1- (3,4-Dichlorophenyl) -3- [4- (pyrrolidin-1-yl) butoxy] -1H-pyrazole hydrochloride,
[0198] [53] 4- [1- (3,4-Dichlorophenyl) -1H-pyrazol-3-yloxy] -N, N-diethylbutan-1-amine oxalate,
[0199] [54] N-benzyl-4- [1- (3,4-dichlorophenyl) -1H-pyrazol-3-yloxy] -N-methylbutan-1-amine oxalate,
[0200] [55] 4- [1- (3,4-Dichlorophenyl) -1H-pyrazol-3-yloxy] -N- (2-methoxyethyl) -N-methylbutan-1-amine oxalate,
[0201] [56] 4- {4- [1- (3,4-Didorophenyl) -1H-pyrazol-3-yloxy] butyl} thiomorpholine oxalate,
[0202] [57] 1- [1- (3,4-Dichlorophenyl) -5-methyl-3- (2-morpholinoethoxy) -1H-pyrazol-4-yl] ethanone oxalate, [58] 1- [1-] oxalate (3,4-dichlorophenyl) -5-methyl-3- [2- (pyrrolidin-1-yl) ethoxy] -1H-pyrazol-4-yl} ethanone,
[0203] [59] 1- {1- (3,4-Dichlorophenyl) -5-methyl-3- [2- (piperidin-1-yl) ethoxy] -1H-pyrazol-4-yl} ethanone oxalate,
[0204] [60] 1- {1- (3,4-Dichlorophenyl) -3- [2- (diethylamino) ethoxy] -5-methyl-1H-pyrazol-4-yl} ethanone oxalate,
[0205] [61] 4- {2- [5-methyl-1- (naphthalen-2-yl) -1H-pyrazol-3-yloxy] ethyl} morpholine,
[0206] [62] N, N-diethyl-2- [5-methyl-1- (naphthalen-2-yl) -1H-pyrazol-3-yloxy] ethanamine,
[0207] [63] 1- {2- [5-methyl-1- (naphthalen-2-yl) -1H-pyrazol-3-yloxy] ethyl} piperidine hydrochloride,
[0208] [64] 5-Methyl-1- (naphthalen-2-yl) -3- [2- (pyrrolidin-1-yl) ethoxy] -1H-pyrazole hydrochloride,
[0209]
[0210] its salts, different alternative salts, solvates or pharmaceutically acceptable prodrugs.
[0211]
[0212] In a more preferred embodiment of the use as defined above, the compound is 4- {2- [5-methyl-1- (naphthalen-2-yl) -1H-pyrazol-3-yloxy] ethyl} morpholine or its salts , solvates or a pharmaceutically acceptable prodrug thereof.
[0213]
[0214] In an even more preferred embodiment of the use as defined above, the compound is 4- {2- [5-methyl-1- (naphthalen-2-yl) -1H-pyrazol-3-yloxy] ethyl hydrochloride} morpholine or a prodrug or solvates thereof.
[0215]
[0216] The term "alkyl" refers to a radical of the linear or branched hydrocarbon chain type consisting of carbon and hydrogen atoms, which does not contain unsaturation, having from one to eight carbon atoms and which is bound to the remainder by a linkage. simple, for example, methyl, ethyl, n-propyl, / -propyl, n-butyl, f-pentyl, n-pentyl, etc. The alkyl radicals may be optionally substituted with one or more substituents such as an aryl, halo, hydroxy, alkoxy, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, amino, nitro, mercapto, alkylthio, etc. If it is substituted with an aryl, it corresponds to an "arylalkyl or aralkyl" radical, such as benzyl and phenethyl.
[0217] The term "alkenyl" refers to an alkyl radical having at least two carbon atoms and having one or more unsaturated bonds.
[0218]
[0219] The term "cycloalkyl" refers to a stable 3- to 10-membered mono- or bicyclic radical which is saturated or partially saturated, and which is composed solely of carbon and hydrogen atoms, such as cyclohexyl or adamantyl. The cycloalkyl radical may be optionally substituted with one or more substituents such as alkyl, halo, hydroxy, amino, cyano, nitro, alkoxy, carboxy, alkoxycarbonyl, etc.
[0220]
[0221] The term "aryl" refers to radicals of one or more rings, including the radicals of several rings containing separated and / or condensed aryl groups. Typical aryl groups contain from 1 to 3 separate or condensed rings and from 6 to about 18 ring carbon atoms, such as a phenyl, naphthyl, indenyl, phenanthryl or anthracyl radical. The aryl radical may be optionally substituted with one or more substituents such as hydroxy, mercapto, halo, alkyl, phenyl, alkoxy, haloalkyl, nitro, cyano, dialkylamino, aminoalkyl, acyl, alkoxycarbonyl, etc.
[0222]
[0223] The term "heterocyclyl" refers to a ring radical of 3 to 15 members composed of carbon atoms and one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, preferably a ring of 4 to 8 members with one or more heteroatoms, more preferably a 5 or 6 membered ring with one or more heteroatoms. It can be aromatic or non-aromatic. For the purposes of this invention, the heterocycle may be a monocyclic, bicyclic or tricyclic ring system, which may include fused ring systems; and the nitrogen, carbon or sulfur atoms of the heterocyclyl radical may be optionally oxidized; the nitrogen atom may optionally be quaternized; and the heterocyclyl radical may be partially or completely saturated or aromatic. Examples of such heterocycles include, without limitation, azepines, benzimidazole, benzothiazole, furan, isothiazole, imidazole, indole, piperidine, piperazine, purine, quinoline, thiadiazole, tetrahydrofuran, coumarin, morpholine; pyrrole, pyrazole, oxazole, isoxazole, triazole, imidazole, etc.
[0224]
[0225] The term "alkoxy" refers to a radical of the formula -ORa, wherein Ra is an alkyl radical as defined above, for example, methoxy, ethoxy, propoxy, etc.
[0226] The term "amino" refers to a radical of formula -NH2, -NHRa or -NRaRb, optionally quaternized, where Ra and Rb are an alkyl radical as defined above, for example, methoxy, ethoxy, propoxy, etc.
[0227]
[0228] The term "halo" or "hal" refers to bromine, chlorine, iodine or fluorine.
[0229]
[0230] The term "condensed ring system" refers to a polycyclic ring system containing fused rings. Typically, the fused ring system contains 2 or 3 rings and / or up to 18 ring atoms. As defined above, cycloalkyl radicals, aryl radicals and heterocyclyl radicals can form fused ring systems. Therefore, the fused ring system may be aromatic, partially aromatic or non-aromatic and may contain heteroatoms. A spiro-type ring system is not a condensed polycyclic system according to this definition, but the condensed polycyclic ring systems of the invention may have spiro-type rings attached to them by a single ring atom of the system. Some examples of fused ring systems are, without limitation, adamantyl, naphthyl (e.g., 2-naphthyl), indenyl, phenanthryl, anthracyl, pyrenyl, benzimidazole, benzothiazole, etc.
[0231]
[0232] Unless specifically indicated otherwise in the specification, all groups may be optionally substituted where appropriate. References herein to substituted groups in the compounds of the present invention refer to the specified moiety that may be substituted at one or more available positions with one or more suitable groups, for example, halogen such as fluoro, chloro, bromo or iodo ; cyano; hydroxyl; nitro; azido; alkanoyl such as a C 1-6 alkanoyl group, such as, for example, acyl and the like; carboxamido; alkyl groups including those groups having from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms and more preferably from 1 to 3 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated bonds and from 2 to about 12 carbons or from 2 to about 6 carbon atoms; alkoxy groups having one or more bonds with oxygen and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those moieties having one or more thioether type bonds and from one to 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; alkylsulfinyl groups including those moieties having one or more sulfinyl type bonds and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; alkylsulfonyl groups including those residues having one or more sulfonyl type bonds and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; aminoalkyl groups such as groups having one or more N atoms and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; carbocyclic aryl having 6 or more carbons, in particular phenyl or naphthyl, and aralkyl such as benzyl. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position in the group and each substitution is independent of the others.
[0233]
[0234] Unless otherwise specified, it is also intended that the compounds of the invention include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, the compounds that have the structures of the present document except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon with a carbon enriched in 13C or 14C or a nitrogen enriched in 15N are included in the scope of this invention.
[0235]
[0236] The term "pharmaceutically acceptable salts, solvates, prodrugs" refers to any salt, ester, solvate or any other pharmaceutically acceptable compound which, when administered to the recipient, is capable of providing (directly or indirectly) a compound such as those described in the present. However, it will be appreciated that salts that are not pharmaceutically acceptable also fall within the scope of the invention, since they may be useful in the preparation of pharmaceutically acceptable salts. The preparation of salts, prodrugs and derivatives can be carried out by methods known in the art.
[0237]
[0238] For example, the pharmaceutically acceptable salts of the compounds provided herein are synthesized from the starting compound containing a basic or acidic moiety by conventional chemical methods. In general, such salts are prepared, for example, by reacting the free acid or base forms of these compounds with a stoichiometric amount of the base or the appropriate acid in water or in an organic solvent or in a mixture of both. In general, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. Examples of the acid addition salts include mineral acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, and organic acid addition salts such as, for example, acetate, maleate , fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate and p-toluenesulfonate. Examples of alkali addition salts include inorganic salts such as, for example, sodium, potassium, calcium, ammonium salts, magnesium, aluminum and lithium, and organic alkali salts such as, for example, ethylenediamine, ethanolamine, W, W-dialkylene ethanolamine, triethanolamine, glucamine and salts of basic amino acids.
[0239]
[0240] Preferred derivatives or prodrugs in particular are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., allowing an orally administered compound to be absorbed more easily and into the blood) or that increase the supply of the initial compound to a biological compartment (for example, the brain or the lymphatic system) with respect to the initial species.
[0241]
[0242] Any compound that is a prodrug of a compound of formula (I) is contemplated by the scope of the invention. The term "prodrug" is used in its broadest sense and encompasses those derivatives that are converted in vivo into the compounds of the invention. Such derivatives will be obvious to those skilled in the art and include, depending on the functional groups present in the molecule and without limitation, the following derivatives of the compounds herein: esters, amino acid esters, phosphate esters, sulfonate esters of salts metallic, carbamates and amides. Those skilled in the art will be familiar with examples of well known methods for producing a prodrug of a particular active compound and these can be consulted, for example, in Krogsgaard-Larsen et al. "Textbook of Drug Design and Discovery" Taylor and Francis (April 2002).
[0243]
[0244] The compounds of the invention may be in crystalline form either as free compounds or as solvates and both forms are intended to be within the scope of the present invention. In general, solvation methods are known in the art. Suitable solvates are pharmaceutically acceptable solvates. In a particular embodiment, the solvate is a hydrate.
[0245]
[0246] The compounds of general formula (I) or their salts or solvates are preferably in a pharmaceutically acceptable or substantially pure form. By the term "pharmaceutically acceptable form" it is meant, inter alia, that it has a pharmaceutically acceptable level of purity, excluding normal pharmaceutical additives such as diluents and carriers and not including a material considered to be toxic with normal dosage levels. The purity levels for the drug substance are preferably greater than 50%, more preferably greater than 70%, most preferably greater than 90% In a preferred embodiment, it is greater than 95% of the compound of formula (I) or its salts, solvates or prodrugs.
[0247]
[0248] The compounds of the present invention represented by the general formula (I) described above may include enantiomers depending on the presence of chiral centers or isomers depending on the presence of multiple bonds (eg, Z, E). Enantiomers, diastereoisomers or individual isomers and their mixtures are within the scope of the present invention.
[0249]
[0250] The compounds of general formula (I) and their salts or solvates can be prepared as indicated in the earlier application WO2006 / 021462.
[0251]
[0252] The reaction products obtained can be purified, if desired, by conventional methods, such as crystallization and chromatography. When the methods described above for the preparation of the compounds of the invention produce mixtures of stereoisomers, these isomers can be separated by conventional techniques such as preparative chromatography. If there are chiral centers, the compounds can be prepared in racemic form or the individual enantiomers can be prepared by enantiospecific synthesis or by resolution.
[0253]
[0254] A preferred pharmaceutically acceptable form is the crystalline form, which includes said crystalline form in a pharmaceutical composition. In the case of salts and solvates, the additional solvent and ionic moieties must also be non-toxic. The compounds of the invention may have different polymorphic forms; it is intended that the invention encompass all these forms.
[0255]
[0256] As used herein, the terms "treat", "treatment" and the term "treating" include the eradication, elimination, reversal, alleviation, modification or control of diabetes, metabolic syndrome, hyperglycemia and / or its related symptoms. In some embodiments, the invention is directed to the treatment of diabetes associated glycemia by lowering blood glucose levels.
[0257]
[0258] Another aspect of this invention relates to a method for treating diabetes, wherein the method or methods comprise administering to a patient in need of such a treatment a therapeutically effective amount of a sigma ligand, more particularly a compound of general formula (I) as defined above or one of its pharmaceutical compositions.
[0259]
[0260] Another aspect of the invention is a method of treating a patient suffering from diabetes by controlling glycemia associated with diabetes by reducing blood glucose levels, which comprises administering to the patient in need of said treatment a therapeutically effective amount of a ligand. of sigma, more particularly a sigma ligand of formula (I) as defined above.
[0261]
[0262] Another aspect of the invention is a method of treating a patient suffering from diabetes, comprising administering to the patient in need of such treatment a therapeutically effective amount of a sigma ligand, more particularly a sigma ligand of formula (I) as previously defined as adjuvant therapy.
[0263]
[0264] Another aspect of the invention is a method of treating a patient suffering from metabolic syndrome, in particular, metabolic syndrome associated with diabetes, which comprises administering to the patient in need of such treatment a therapeutically effective amount of a sigma ligand, more particularly a sigma ligand of formula (I) as defined above.
[0265]
[0266] Another aspect of the invention relates to a method of treating a patient suffering from hyperglycemia, which comprises administering to the patient in need of such treatment a therapeutically effective amount of sigma ligand, more particularly a sigma ligand of formula (I) such as has defined previously.
[0267]
[0268] In another aspect, the invention relates to the use of a sigma ligand, more particularly the compounds of general formula defined above in the preparation of a medicament for the treatment of diabetes.
[0269]
[0270] In another aspect, the invention relates to the use of a sigma ligand, more particularly of the compounds of general formula (I) as defined above, in the preparation of a medicament for controlling glycemia associated with diabetes by reducing glucose levels.
[0271] In another aspect, the invention relates to the use of a sigma ligand, more particularly of the compounds of general formula (I) as defined above, in the preparation of a medicament for adjuvant therapy for diabetes.
[0272]
[0273] In another aspect, the invention relates to the use of a sigma ligand, more particularly of the compounds of general formula (I) as defined above, in the preparation of a medicament for the treatment of the metabolic syndrome, in particular, the syndrome metabolic associated with diabetes.
[0274]
[0275] In another aspect, the invention relates to the use of a sigma ligand, more particularly the compounds of general formula (I) as defined above, in the preparation of a medicament for the treatment of hyperglycemia.
[0276]
[0277] The present invention further provides pharmaceutical compositions comprising a compound of this invention, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomers thereof, together with a pharmaceutically acceptable carrier, adjuvant or vehicle, for administration to a patient.
[0278]
[0279] In another aspect, the invention therefore relates to the use as defined above of a pharmaceutical composition comprising a compound as defined above, wherein the composition further comprises a pharmaceutically acceptable carrier, adjuvant and / or carrier.
[0280]
[0281] Examples of pharmaceutical compositions include any solid composition (tablets, pills, capsules, granules, etc.) or liquid (solutions, suspensions or emulsions) for oral, topical or parenteral administration.
[0282]
[0283] In a preferred embodiment, the pharmaceutical compositions are in oral form, either solid or liquid. Pharmaceutical forms suitable for oral administration may be tablets, capsules, syrups or solutions and may contain conventional excipients known in the art such as binding agents, for example, syrup, gum arabic, gelatin, sorbitol, tragacanth gum or polyvinylpyrrolidone; filling materials, for example, lactose, sugar, corn starch, calcium phosphate, sorbitol or glycine; lubricants for forming tablets, for example, magnesium stearate; disintegrants, for example, starch, polyvinylpyrrolidone, sodium starch glycollate or cellulose microcrystalline; or pharmaceutically acceptable wetting agents such as sodium lauryl sulfate.
[0284]
[0285] The solid oral compositions can be prepared by conventional methods of combination, filling or tabletting. Repeated combination operations can be used to distribute the active ingredient for all those compositions that employ large amounts of filler materials. Such operations are conventional in the art. The tablets can be prepared, for example, by wet or dry granulation and optionally can be coated according to methods well known in the usual pharmaceutical practice, in particular with an enteric coating.
[0286]
[0287] The pharmaceutical compositions can also be adapted for parenteral administration, such as solutions, suspensions or sterile lyophilized products in the appropriate unit dosage form. Suitable excipients may be used, such as dough-forming agents, buffering agents or surfactants.
[0288]
[0289] The formulations mentioned will be prepared using standard methods such as those described or referred to in the Spanish and US Pharmacopoeias, and in similar reference texts.
[0290] The administration of the compounds or compositions of the present invention can be carried out by any suitable method, such as intravenous infusion, oral preparations and intraperitoneal and intravenous administration. Oral administration is preferred because of the patient's convenience and the chronic nature of the diseases to be treated.
[0291]
[0292] In general, the effective amount administered of a compound of the invention will depend on the relative efficacy of the selected compound, the severity of the disorder being treated and the weight of the patient. However, the active compounds will normally be administered one or more times per day for example 1, 2, 3 or 4 times a day, with typical total daily doses in the range between 0.1 and 1000 mg / kg / day.
[0293]
[0294] In a preferred embodiment of the use of the compounds of formula (I) of the invention, the compounds, optionally in the form of a pharmaceutical composition, are administered once a day.
[0295] In a preferred embodiment of the use of the compounds of the invention, the sigma ligand of general formula (I) is administered as a daily dose comprised between 100 mg and 600 mg per day. Even more preferably, the sigma ligand of general formula (I) is administered as a daily dose comprised between 200 mg and 400 mg per day.
[0296]
[0297] The compounds and compositions of this invention can be used with other drugs to provide a combination therapy. The other drugs can be part of the same composition or can be provided as an independent composition that can be administered at the same time or at a different time.
[0298] Advantageously, the other drugs are selected among the known drugs currently used in the treatment of diabetes, especially of type 2 diabetes.
[0299]
[0300] The following examples are provided solely as a further illustration of the invention and should not be construed as a definition of the limits of the invention.
[0301] EXAMPLES
[0302] Example 1
[0303] Synthesis of 4- {2- [5-methyl-1- (naphthalen-2-yl) -1H-pyrazol-3-yloxy] ethyl} morpholine (compound 63) and its hydrochloride salt
[0304]
[0305]
[0306]
[0307]
[0308] Compound 63 can be prepared as described in the earlier application WO2006 / 021462 (compound 63 is example 61 in WO2006 / 021462). Your hydrochloride can be obtained according to the following procedure:
[0309]
[0310] Compound 63 (6.39 g) was dissolved in ethanol saturated with HCl, then the mixture was stirred for several minutes and evaporated to dryness. The residue was crystallized from isopropanol. From the mother liquors of the first crystallization a second crystallization was obtained by its concentration. Both combined crystallizations generated 5.24 g (63%) of the corresponding hydrochloride salt (m.p. = 197-199 ° C).
[0311]
[0312] 1 H-NMR (DMSO-de) 6 ppm: 10.85 (sa, 1H), 7.95 (m, 4H), 7.7 (dd, J = 2.2, 8.8 Hz, 1H), 7 , 55 (m, 2H), 5.9 (s, 1H), 4.55 (m, 2H), 3.95 (m, 2H), 3.75 (m, 2H), 3.55-3, 4 (m, 4H), 3.2 (m, 2H), 2.35 (s, 3H).
[0313]
[0314] Purity by HPLC: 99.8%.
[0315]
[0316] Pharmacological data
[0317]
[0318] Materials and methods
[0319]
[0320] Animals
[0321] Six-week-old male ZDF rats or their respective control (Zucker age-matched non-diabetic rats were obtained
[0322] LEAN) by Charles River Laboratories (Reseach Models, Barcelona, Spain). The animals were housed in a certified animal facility, in cages (2-3 animals) and environmentally controlled conditions were maintained (temperature 20 ° C, humidity 60%) with a light / dark cycle of 12 h until they reached 15 weeks of life. The animals were kept on a Purina 5008 diet (16.7 kcal% fat) and sterile running water, food and water being available at will throughout the experimental period. In this model for non-insulin-dependent diabetes mellitus, hyperglycemia and insulin resistance begin to develop at approximately 7 weeks of age and glucose levels reach a maximum (more than 300 mg / dl) at 15-16 weeks of age. age (Peterson et al., 1990).
[0323]
[0324] All the experimental protocols were approved by the Ethical Committee of the Rey Juan Carlos University and were carried out strictly in accordance with the EC norms for the use and care of experimental animals (2010/63 / EU).
[0325]
[0326] Glycemia
[0327] The glucose levels were measured daily without fasting in the morning (9 h) using a glucose strip test (Glucocard sensor, Arkray, Inc. Kyoto, Japan), throughout the experimental period (weeks 7, 10, 13, 14 and 15).
[0328]
[0329] Experimental protocol
[0330] After one week of adaptation (week 7 of life), non-fasting glucose levels were controlled in LEAN and ZDF rats for the first time to facilitate the detection of the development of diabetes and neuropathies.
[0331] Behavioral tests were repeated at the end of week 13 of age and then the ZDF rats were randomly assigned to two separate groups for treatment with a single dose of Example 1 (64 mg / kg ip, 0.5 ml, n = 8) or with the same volume of saline solution (n = 7), the group of LEAN rats (n = 7) was treated with saline.
[0332]
[0333] The subchronic treatment began 24 hours after this first administration. The rats received two daily intraperitoneal injections for 14 days (weeks 14 and 15) of the compound of Example 1 (25 mg / kg) or saline.
[0334]
[0335] The glycemia was controlled throughout the experimental period.
[0336]
[0337] Example 2: Glycemia in ZDF rats treated with Example 1
[0338] The animals were accustomed to the corresponding test environments two days before the experiment by leaving them inside the recording device for ten minutes.
[0339]
[0340] The ZDF rats showed an average blood glucose concentration of 88.1 ± 5.1, 329.3 ± 26.0, and 413.6 ± 22.6 mg / dl, in weeks 7, 10 and 13, respectively, the difference being the values of weeks 10 and 13 versus week 7 were statistically significant (p <0.001).
[0341] The mean blood glucose concentration of LEAN was 64.8 ± 1.4, 60.6 ± 1.3, and 69.9 ± 2.6 mg / dl, at weeks 7, 10, and 13, respectively. These values were significantly different from those recorded in the ZDF rats treated with saline and with Example 1 (p <0.001).
[0342] Non-fasting glucose levels in ZDF rats were slightly but significantly (p <0.01) reduced compared to the first administration of Example 1 compared to the values recorded in ZDF animals treated with saline (Figure 1).
[0343]
[0344] One-way ANOVA followed by a Bonferroni post hoc test was used for the statistical analysis of blood glucose differences between the ZDF rats treated with saline and with Example 1 (** p <0.01). Two-way ANOVA was used followed by post hoc Bonferroni test when body weight was compared between the three groups (+ p <0.05; + p <0.01; ++ p <0.001 vs. LEAN) (N = 7-8) .
[0345]
[0346] In summary, in the results obtained in Example 2, the compound of Example 1 shows a significant reduction in blood glucose.
[0347] Therefore, the compound of Example 1 and the other compounds of general formula (I) will be useful in the treatment of diabetes, metabolic syndrome, hyperglycemia, etc.

权利要求:
Claims (15)
[1]
1. A compound that binds to the sigma-1 receptor for use in the treatment of diabetes.
[2]
2. A compound that binds to the sigma-1 receptor for use in the control of blood glucose associated with diabetes by reducing blood glucose levels.
[3]
3. A compound that binds to the sigma-1 receptor for use as adjuvant therapy for diabetes.
[4]
4. A compound that binds to the sigma-1 receptor for use in the treatment of the metabolic syndrome, preferably the metabolic syndrome associated with diabetes, preferably to type 2 diabetes.
[5]
5. A compound that binds to the sigma-1 receptor for use in the treatment of hyperglycemia.
[6]
6. The compound for use according to any of claims 1 to 5, wherein the compound has the general formula (I):

[7]
7. The compound for use according to any of claims 1 or 6, wherein the compound is characterized in that R1 is hydrogen.
[8]
8. The compound for use according to any of claims 1 or 7, wherein the compound is characterized in that R2 is H or alkyl, preferably methyl or H.
[9]
9. The compound for use according to any of claims 1 to 8, wherein the compound is characterized in that R3 and R4 together with the phenyl form a naphthyl group.
[10]
The compound for use according to any one of claims 1 to 9, wherein the compound is characterized in that n is selected from 2, 3 and 4, more preferably n is 2.
[11]
11. The compound for use according to any of claims 1 to 10, wherein the compound is characterized in that R5 and R6, together, form a morpholin-4-yl group.
[12]
12. The compound for use according to any of claims 1 to 11, wherein the compound is 4- {2- [5-methyl-1- (naphthalen-2-yl) -1H-pyrazol-3-yloxy] ethyl} morpholine or a solvate or pharmaceutically acceptable prodrug thereof
[13]
The compound for use according to claim 12, wherein the compound is 4- {2- [5-methyl-1- (naphthalen-2-yl) -1H-pyrazol-3-yloxy] ethyl hydrochloride} morpholine or a solvate or prodrug thereof.
[14]
The compound for use according to any of claims 1 to 13, wherein the compound is selected from a sigma receptor antagonist, a neutral antagonist, a reverse agonist or a partial antagonist.
[15]
15. A pharmaceutical composition for use according to claims 1 to 14, wherein the composition further comprises a pharmaceutically acceptable carrier, adjuvant and / or carrier.

类似技术:

公开号 | 公开日 | 专利标题

US20210363155A1|2021-11-25|4-phenylpiperidines, their preparation and use

ES2392193T3|2012-12-05|Sigma receptor inhibitors

ES2709034T3|2019-04-12|Pyrimido [4,5-b] quinoline-4,5 | -diones as suppressors of nonsense mutations

PT2089367E|2012-02-01|Pyrazoline compounds as mineralocorticoid receptor antagonists

TWI688565B|2020-03-21|Naphthyridinedione derivatives

CA2930053A1|2015-06-11|Use of benzimidazole-proline derivatives

US20210347742A1|2021-11-11|Cftr regulators and methods of use thereof

ES2251316B1|2007-03-16|SIGMA RECEIVER INHIBITORS.

KR20170096130A|2017-08-23|Use of sigma receptor ligands in osteoarthritis

ES2700448A2|2019-02-15|Sigma ligands for use in the treatment of diabetes and metabolic syndrome

TW201328695A|2013-07-16|Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders

ES2743184T3|2020-02-18|Pyrimido [4,5-b] quinolin-4,5 | -dione derivatives as suppressors of terminator mutations

WO2019068771A1|2019-04-11|Use of sigma receptor ligands in age-related cognitive impairments

JP6526064B2|2019-06-05|Pyridopyrimidinedione derivatives

JP2018500382A|2018-01-11|New calcium regulator

ES2701975A2|2019-02-26|Use of sigma receptor ligands in post-herpetic pain

BR112019013954A2|2020-02-11|METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

EP3328365A1|2018-06-06|Use of sigma receptor ligands in dyslipidemia

同族专利:

公开号 | 公开日

WO2017211765A1|2017-12-14|

ES2700448R1|2019-02-26|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

EP1404669A2|2001-05-16|2004-04-07|Vertex Pharmaceuticals Incorporated|Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases|

WO2007098939A1|2006-02-28|2007-09-07|Laboratorios Del Dr. Esteve, S.A.|Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome|

MX2008011016A|2006-03-01|2008-09-08|Esteve Labor Dr|Pyrazole derivatives as sigma receptor inhibitors.|

EP2524694A1|2011-05-19|2012-11-21|Laboratorios Del. Dr. Esteve, S.A.|Use of sigma ligands in diabetes type-2 associated pain|

SI3104847T1|2014-02-07|2021-07-30|Tamogatott Kutatoscoportok Irodaja|Novel use of sigma-1 receptor agonist compounds|WO2020113094A1|2018-11-30|2020-06-04|Nuvation Bio Inc.|Pyrrole and pyrazole compounds and methods of use thereof|

法律状态:
2019-02-15| BA2A| Patent application published|Ref document number: 2700448 Country of ref document: ES Kind code of ref document: A2 Effective date: 20190215 |

2019-02-26| EC2A| Search report published|Ref document number: 2700448 Country of ref document: ES Kind code of ref document: R1 Effective date: 20190219 |

2019-06-24| FA2A| Application withdrawn|Effective date: 20190618 |

优先权:

申请号 | 申请日 | 专利标题

EP16382261|2016-06-07|

PCT/EP2017/063616|WO2017211765A1|2016-06-07|2017-06-05|Sigma ligands for use in the treatment of diabetes and metabolic syndrome|

[返回顶部]